The Severity of COVID-19 in Diabetes Patients

Danao, Kishor; Rokde, Vijayshri; Bali, Nikhil; Mahajan, Ujwala

doi:10.2174/1573399819666221006103113

CDR

2023

DOI: 10.2174/1573399819666221006103113

|View full text |Cite

The Severity of COVID-19 in Diabetes Patients

Kishor Danao¹,

Vijayshri Rokde²,

Nikhil Bali

et al.

Abstract: Background and aims: Diabetic patients are significantly stimulated by Covid-19 infection. The dreadful risk of covid-19 mortality may be affected. In order to preserve precious lives, it is essential to comprehend how diabetes and COVID-19 are related, as well as how to manage diabetes. We aimed to focus on the mechanism, impact, and drug treatment of diabetes in covid-19 patients. Methods: A comprehensive scrutiny of the published literature in diverse pharma¬ceutical and medical databases such as Google S… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2025

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Insulin has involved in the metabolisms of kinds of macromolecules like fats, proteins, and carbohydrates. 18 Thus, the deflection in the secretion or release may hamper all related functions. Therefore, the free unsaturated fats and glycerol levels rise in the blood.…”

mentioning

confidence: 99%

In Silico Prediction of Antidiabetic Activity of Phytoconstituents of Pterocarpus Marsupium Targeting α-Amylase Enzyme

Danao¹,

Kale²,

Rokde³

et al. 2023

Biosci., Biotech. Res. Asia

Self Cite

View full text Add to dashboard Cite

Background Diabetes is characterized by a metabolic imbalance of blood sugar levels. α-amylase enzyme hydrolyzed starch into glucose units. Current therapy has significant side effects. Current investigation of in silico antidiabetic evaluation of phytoconstituents of Pterocarpus marsupium targeting α-amylase. Methods In silico studies were investigated to determine the binding affinity of phytoconstituents of Pterocarpus marsupium in additional with the crystal structure of α-amylase (PDB ID: 3BC9) with help of Pyrx in autodock vina software. Further, investigate the amino acid interaction residue and impacts on the inhibitory potential of the active phytoconstituents. Additionally, the pharmacokinetics and SwissADME and pkCSM were used as online servers for the toxic effects research. Further, studied the pocket region of amino acid for the binding of phytoconstituents using the Ramachandran plot. Result Molecular docking results proposed that pterostilbenes and liquirtigenin (-8.1 kcal/mol) had best docked against α-amylase as related to native ligand (-5.6 kcal/mol) and metformin (-5.3 kcal/mol). The active phytoconstituent has actively participated in interaction with the amino acid residue leads to blockage of α-amylase activity. Furthermore, the pharmacokinetic and In ADMET investigations, the phytoconstituents toxicological values are within allowable ranges. Conclusion The most promising outcome was revealed by the phytoconstituents of Pterocarpus marsupium that bind to α -amylase. However, it encourages the traditional practice of Pterocarpus marsupium and delivers vital information in drug development and clinical treatment. It promotes traditional approach of Pterocarpus marsupium and provides crucial knowledge for medical research and therapeutic care.

show abstract

mentioning

confidence: 99%

In Silico Prediction of Antidiabetic Activity of Phytoconstituents of Pterocarpus Marsupium Targeting α-Amylase Enzyme

Danao¹,

Kale²,

Rokde³

et al. 2023

Biosci., Biotech. Res. Asia

Self Cite

View full text Add to dashboard Cite

show abstract

Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment

Danao,

Rokde,

Nandurkar

et al. 2025

CDR

View full text Add to dashboard Cite

The overexpression of the Protein Tyrosine Phosphatase 1B (PTP1B), a key role in the development of insulin resistance, diabetes (T2DM) and obesity, seems to have a substantial impact as a negative regulator of the insulin and leptin signaling pathways. Therefore, inhibiting PTP1B is a prospective therapeutic approach for the treatment of diabetes and obesity. However, the pyrazole scaffold is expected to be of significant pharmaceutical interest due to its broad spectrum of pharmacological actions. This study aims to focus on the significance of pyrazole scaffold in medicinal chemistry, the impact of PTP1B in diabetes and the therapeutic approach of pyrazole scaffold to treat T2DM. A comprehensive analysis of the published literature in several pharmaceutical and medical databases, such as the Web of Science (WoS), PubMed, ResearchGate, ScienceDirect etc., were indeed successfully completed and classified accordingly Results:: As reviewed, the various derivatives of the pyrazole scaffold exhibited prominent PTP1B inhibitory activity. The result showed that derivatives of oxadiazole and dibenzyl amine, chloro substituents, 1, 3-diaryl pyrazole derivatives with rhodanine-3-alkanoic acid groups, naphthalene and also 1, 3, 5-triazine-1H-pyrazole-triazolothiadiazole derivatives, octyl and tetradecyl derivative, indole- and N-phenylpyrazole-glycyrrhetinic acid derivatives with trifluoromethyl group, 2,3-pyrazole ring-substituted-4,4-dimethyl lithocholic acid derivatives with 4- fluoro phenyl substituted and additional benzene ring in the pyrazole scaffold significantly inhibits PTP1B. In silico study observed that pyrazole scaffold interacted with amino acid residues like TYR46, ASP48, PHE182, TYR46, ALA217 and ILE219. Diabetes is a metabolic disorder that elevates the risk of mortality and severe complications. PTP1B is a crucial component in the management of diabetes and obesity. As a result, PTP1B is a promising therapeutic target for the treatment of T2DM and obesity in humans. We concluded that the pyrazole scaffold has prominent inhibitory potential against PTP1B.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Severity of COVID-19 in Diabetes Patients

Cited by 2 publications

References 38 publications

In Silico Prediction of Antidiabetic Activity of Phytoconstituents of Pterocarpus Marsupium Targeting α-Amylase Enzyme

In Silico Prediction of Antidiabetic Activity of Phytoconstituents of Pterocarpus Marsupium Targeting α-Amylase Enzyme

Pyrazole Scaffold: Potential PTP1B Inhibitors for Diabetes Treatment

Contact Info

Product

Resources

About